Evolution-adjusted Tumor Pathophysiology:, 2013
The Novel Language of Tumor Biology

Preface. I  Introduction. 1. Communication ─ evolution ─ pathophysiology: An endogenous conjunction ─Instead of an introduction. II  Combined modularized therapies for metastatic tumors: Pointing to central problems of communication among ‘systems participators’ in tumors. 2 Applied systems biology for the control of metastatic cancer: Therapeutic top-down strategy for targeting the tumors’ normativity. 3 Targeting the proangiogenic network in angiosarcomas: Biomodulatory therapy.4 Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis. 5 Redirecting and modulating rationalizations of tumor-immanent normative functions in castration-resistant prostate ancer. III  Social engineering: Biomodulation, either endogenously initiated or by implementation of non-normative boundary conditions. 6 Non-hierarchically organized operations in malignancies: Stromal dysfunction induces hematopoetic malignancies. 7 Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective. 8 Proteome analysis identified the PPARc ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.IV   The tumors’ normativity: Reconstructing and operationalizing starting  points for an evolution theory. 9  The philosophical quest of a cancer cell: Redefining existentialism. 10 The tumor’s normativity: Normative structures, action norms and decision maxims as therapeutic targets for tumor therapy. 11 Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer. V   Evolution theory. 12 Evolution theory: Its practical relevance for understanding tumor development and specifying tumor therapy. 13 Modularity, subjectivity, intersubjectivity and normativity: Clinically applicable operative benchmarks.14 Turning upside down the mode of science to emphasize and harness the impact of environmental communicative events. VI   From genome- or organ-centric to rationalization-centric systematization of tumors. 15 Purposive-rational tumor therapy: Exploiting the tumor’s ‘living world’ for diversifying, specifying and personalizing tumor therapy. 16 Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications.VII  Reconstruction of tumor-immanent normative functions, structures and decision maxims (hubs). 17 Bridging a diagnostic and therapeutic gap: Selecting, assessing and categorizing tumor-associated normative notions. 18 Personalizing tumor pathophysiology by diagnosing developmental problems in tumors with imaging techniques. 19  Biologic memory: Induction by metronomically administered combined modularized therapy. VIII The tool of rationalizations constituting tumor-associated normative notions: The non-genomic counterpart of the tumor genome and therefore, an important therapeutic target for diversifying palliative care. 20  Diversifying and specifying palliative care for patients with metastatic cancer by therapeutic implementation of non-normative boundary conditions. 21 Targeting a hallmark of cancer: Simultaneous inflammation and tumor control for palliative care in metastatic cancer. IX  Novel clinical and pharmaceutical technology for bioengineering tumor response. 22 Combined modularized tumor therapy ─ tumor biology ─ and prognostic factors: Bioengineering tumor response. X   Objectifying the systems objects’ subjectivity in biological systems: A novel reification of the scientific picture about the ‘objective’ world. 23 The systems objects’ subjectivity as scientific object. Index.

Applied systems biology

Personalizing tumor therapy with novel methodological approaches

Drafting the non-genomic counterpart of the genome: Rationalizations constituting tumor-associated normative notions (angiogenesis, inflammation, immune response etc.)

Reconstructing and operationalizing starting points for an evolution theory

Evolution-adjusted tumor pathophysiology as novel clinical and pharmaceutical technology for bioengineering tumor response